Abstract
Ovarian cancer remains the most lethal gynecological cancer in women despite decades of treatment with classic and new targeted therapies. Chemoresistant ovarian cancer accounts for the 5-year cause-specific survival of less than 25% in women with advanced stage ovarian cancers (stage III or IV). Platinum resistance continues to be a significant obstacle in the pursuit of prolonged survival and cure in patients with recurrent ovarian cancer. Immunotherapy is a promising therapeutic strategy for chemoresistant ovarian cancer. The tumor microenvironment in ovarian cancer is characteristically immunosuppressive to infiltrating cytotoxic T cells. Thus the goal of immune-based therapies is twofold: overcome this immunosuppression and enhance tumor destruction. In this chapter, we discuss the ongoing preclinical studies and clinical trials investigating vaccines and other immunotherapies in patients with platinum-resistant ovarian cancer. Specifically, we present key advances in the development of cancer vaccines and adjuvants for the generation of optimal immunogenicity and immuno-persistence. Finally, we explore future immune-based strategies for targeting and eradicating chemoresistant ovarian cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
